Sharemaestro Newsreel

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary

Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …

Clover Health Is Proving Its Profit Model (NASDAQ:CLOV)

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

Wedbush reiterated its "outperform" rating on Zenas BioPharma (NASDAQ:ZBIO) with a $45 price target, indicating a potential 54.11% upside. Despite this positive analyst sentiment, the company reported a significant miss on its quarterly earnings and revenue estimates. Other analysts have also adjusted their ratings, …

Avoro, Aghazadeh report 7.06% Hemab Therapeutics (COAG) ownership stake

Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have collectively reported a beneficial ownership stake of 7.06% in Hemab Therapeutics Holdings, Inc. (COAG). This ownership comprises 3,298,236 shares of common stock, acquired solely for investment purposes on behalf of their respective funds. …

HC Wainwright Has Negative View of Talphera FY2029 Earnings

HC Wainwright has lowered its FY2029 earnings per share estimate for Talphera (NASDAQ:TLPH) to $0.12 from $0.13, while reiterating a "Buy" rating and a $3.00 price target. The firm also projected FY2030 EPS at $0.32. Talphera's stock has a "Hold" consensus rating from analysts, …

Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances

The proposed merger between Crinetics Pharmaceuticals (NASDAQ:CRNX) and Vertex Pharmaceuticals (NASDAQ:VRTX) has progressed after securing regulatory clearances, including the expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and approvals in Austria, Germany, and Australia. The acquisition, valued at approximately $10 billion, is expected …

Equities Analysts Offer Predictions for MNPR FY2029 Earnings

Equities Analysts Offer Predictions for CADL FY2028 Earnings

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which …

Canton Strategic's locking-as-a-service offering generated about $1.3M

Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results

Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100

Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame

Brokers Offer Predictions for RAPP Q1 Earnings

Noble Financial Has Pessimistic View of UNCY Q2 Earnings

PDS Biotechnology shareholders approve charter amendment and director elections

PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …

Omeros: YARTEMLEA Is Off To A Blistering Start (NASDAQ:OMER)

Omeros Corporation has received a Buy rating due to YARTEMLEA's unexpectedly strong launch, generating $28.5 million in net sales and positive operating cash flow in its first full quarter. The drug's adoption is rapidly increasing across transplant centers, with high formulary approval rates and …

Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales

Why is Alpha Cognition stock surging today?

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 4.9% in Tonix Pharmaceuticals Holding Corp., which includes 814,801 shares of common stock. This stake comprises 615,025 shares issuable upon the exercise of warrants. The ownership percentage is calculated based on …

Q3 Earnings Estimate for AptarGroup Issued By Zacks Research

Q3 EPS Estimates for Journey Medical Cut by HC Wainwright

Sidoti Equities Analysts Raise Earnings Estimates for Kamada

Equities Analysts Set Expectations for TCRX FY2026 Earnings

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is brief and does not contain additional details within the provided content. It is published by Investing.com, a financial markets news platform.

Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026

Quince Therapeutics announced a net loss of $75.5 million for Q2 2026, with $116 million in cash, cash equivalents, and investments as of June 30, 2026. The company completed a $115 million private placement concurrent with its acquisition of Orphai and initiated a Phase …

Form 8K Quince Therapeutics Inc For: 14 August By Investing.com

The article reports on Quince Therapeutics Inc.'s Form 8K filing for August 14th. It is a brief announcement from Investing.com, providing basic information about the filing and the company's stock performance on that day.

Anteris Technologies Global (NASDAQ:AVR) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated an "overweight" rating on Anteris Technologies Global (NASDAQ: AVR) with a $15 price target, suggesting a significant upside. Despite weaker-than-expected quarterly results and insider selling, the stock maintains a "Moderate Buy" consensus rating from analysts. The company's stock has shown some …

Insider Spends US$141k Buying More Shares In Embecta

Embecta's President, Devdatt Kurdikar, recently purchased US$141k worth of company stock at US$4.70 per share, increasing his holding by 3.9%. This is the largest insider purchase in the last year, suggesting optimism for the company's future, despite the overall insider ownership being relatively low …

Embecta Corp. SVP Elguicze purchases $93,360 in common stock

Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, recently purchased 20,000 shares of the company's common stock for $93,360. This insider purchase comes after a significant stock decline but a recent rebound, with the company trading at a low P/E ratio. The purchase …

Sirenia Capital (HELP) reports 3.03M-share Cybin stake including warrant shares

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 3,029,500 Common Shares in Cybin Inc., which includes 969,500 shares issuable upon the exercise of warrants. This stake represents 4.8% of Cybin's outstanding Common Shares, based on 61,984,078 shares as of …